Read the 1st publication of the EUROVISCO Group
Y. Henrotin; R. Raman; P. Richette; H. Bard, J. Jerosch; T. Conrozier; X. Chevalier; A. Migliore. Semin Arthritis Rheum. 2015 Apr 30.
The EUROVISCO Group is proud to announce the publication of its first publication in a renowned peer-reviewed journal: Seminars in Arthritis and Rheumatism.
Viscosupplementation (VS) with hyaluronic acid is currently used by physicians to treat osteoarthritis. However, many aspects of this treatment remain questionable and subject of controversy.
A group of 8 experts in this field, from European countries, met to debate on 24 statements previously listed by the group members. Based on an extensive research of the literature and expert opinion, a consensus position has been proposed for each statement.
Agreement was achieved on some recommendations. In particular, the expert achieved unanimous agreement in favor of the following statements:
- VS is an effective treatment for mild to moderate knee OA;
- VS is not an alternative to surgery in advanced hip OA;
- VS is a well-tolerated treatment of knee and other joints OA;
- VS should not be used only in patients who have failed to respond adequately to analgesics and NSAIDs;
- VS is a « positive » indication but not a « lack of anything better » indication;
- The dosing regimen must be supported by evidence-based medicine;
- Cross-linking is a proven means for prolonging IA residence time of HA;
- The best approach to inject accurately knee joint is the lateral mid-patellar one;
- When VS is performed under fluoroscopy, the amount of radiopaque contrast agent must be as low as possible to avoid viscosupplement dilution.
These clear recommendations have been established to help practitioners in the use of viscosupplementation.
Ankle; Consensus; Experts opinion; Hip; Hyaluronan; Hyaluronic acid; Intra-articular injection; Knee; Osteoarthritis; Recommendations; Shoulder; Thumb; Trapezio-metacarpal joint; Treatment; Viscosupplementation